In individuals at intermediate risk for cardiovascular disease, treatment with rosuvastatin but not candesartan plus hydrochlorothiazide lowers cardiovascular disease event rates

Evid Based Med. 2016 Dec;21(6):228-229. doi: 10.1136/ebmed-2016-110523. Epub 2016 Oct 6.

Author

Michael LeFevre¹

Affiliation

¹ Department of Family and Community Medicine, University of Missouri, Columbia, Missouri, USA.

PMID: 27758802
DOI: 10.1136/ebmed-2016-110523

No abstract available

Publication types

Comment

MeSH terms

Antihypertensive Agents
Cardiovascular Diseases
Humans
Hydrochlorothiazide*
Hypertension
Rosuvastatin Calcium*

Substances

Antihypertensive Agents
Hydrochlorothiazide
Rosuvastatin Calcium